thymidine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Blasi, D | 1 |
| Claessen, I | 1 |
| Turksma, AW | 1 |
| van Beek, J | 1 |
| Ten Brinke, A | 1 |
1 other study available for thymidine and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Guidelines for analysis of low-frequency antigen-specific T cell results: Dye-based proliferation assay vs
Topics: Adjuvants, Immunologic; CD4-Positive T-Lymphocytes; Cell Proliferation; DNA Replication; Flow Cytome | 2020 |